Vyome announces Nasdaq approval of merger with ReShape Lifesciences

Vyome Therapeutics announced that The Nasdaq Stock Market has approved its listing upon completion of the company’s previously announced merger with ReShape Lifesciences (RSLS), which is expected to take effect for marketplace purposes with the open of trading on Friday, August 15 under the name Vyome Holdings (HIND), Inc. and the trading symbol “HIND.” “Nasdaq’s approval is right on track and now we are marching forward to ring the bell on our planned listing date this Friday. We look forward to welcoming RSLS shareholders and invite all others who wish to be part of our journey, which I promise will at all times be focused only on shareholder value. If you believe in the global healthcare market, in the opportunities to do business between the US and India, and in the value of a group of smart people driving real innovation across science and AI, you believe in Vyome,” said Krishna Gupta, Chairman of Vyome.